Propper R D, Shurin S B, Nathan D G
N Engl J Med. 1976 Jun 24;294(26):1421-3. doi: 10.1056/NEJM197606242942603.
Treatment of transfusion-induced iron overload by daily intramuscular injection of the chelator desferrioxamine has not produced impressive urinary iron excretion. We attempted to augment net iron excretion by altering both the route and quantity of chelator administered. Two ascorbic acid-replete patients excreted a mean of 14.5 mg of iron per 24 hours after a single intramuscular injection of 750 mg of desferrioxamine. Excretion increased to a mean of 44.9 mg when this dose was delivered by a continuous 24-hour intravenous infusion. When the intravenous dose of chelator was increased incrementally to as high as 16,000 mg per 24 hours, iron excretion increased up to 180 mg per day. At these high-dose levels, efficiency of binding of iron to chelator was compromised. Constant exposure of the labile iron pool to a chelating agent markedly enhances net iron excretion in splenectomized transfusion-dependent patients.
通过每日肌肉注射螯合剂去铁胺来治疗输血引起的铁过载,并未产生令人印象深刻的尿铁排泄量。我们试图通过改变螯合剂的给药途径和剂量来增加铁的净排泄量。两名维生素C充足的患者在单次肌肉注射750毫克去铁胺后,每24小时平均排泄14.5毫克铁。当通过持续24小时静脉输注给予该剂量时,排泄量增加至平均44.9毫克。当螯合剂的静脉剂量逐渐增加至每24小时高达16000毫克时,铁排泄量增加至每天180毫克。在这些高剂量水平下,铁与螯合剂的结合效率受到损害。不稳定铁池持续暴露于螯合剂可显著提高脾切除的输血依赖患者的铁净排泄量。